Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC
The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) with concurrent chemotherapy in the management of stage II and III non-small cell lung cancer (NSCLC).
Nonsmall Cell Lung Cancer|Nonsmall Cell Lung Cancer, Stage II|Nonsmall Cell Lung Cancer Stage III|Unresectable Non-Small Cell Lung Carcinoma
RADIATION: Genomically Guided Radiation Therapy (RT)
Rate of Unacceptable Toxicity, Rate of Unacceptable Toxicity will be measured during 12 week period following study enrollment. Unacceptable toxicity is defined as any grade 4 or 5 adverse event (AE) probably or definitely related to experimental dose escalated radiation therapy, 12 weeks after start of treatment
Freedom from local regional progression (FFLRP), Freedom from local regional progression (FFLRP) will be defined as lack of progression as documented by response assessment imaging following completion of concurrent chemotherapy and radiation., At 2 years|Overall Survival (OS), Overall Survival (OS) will be measured from the date of first treatment to the date of death due to any cause., At 2 years
The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) with concurrent chemotherapy in the management of stage II and III non-small cell lung cancer (NSCLC).